Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | CD38 | P28907 | 9/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.42 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29592899 | 1.00 | POLB (0.49) | POLBLMNACACNA1HCACNA1BCACNA1C | |
| SCHEMBL18685091 | 0.89 | KDM4A (0.48) | POLBSCN9AKDM4AMAPK1ATM | |
| SCHEMBL25306120 | 0.83 | KDM4A (0.44) | POLBSCN9AKDM4AMAPK1ATM | |
| SCHEMBL18685355 | 0.83 | KDM4A (0.44) | POLBSCN9AKDM4AMAPK1ATM | |
| SCHEMBL29473241 | 0.82 | KDM4A (0.43) | POLBSCN9AKDM4AMAPK1ATM | |
| SCHEMBL21987975 | 0.82 | HDAC1 (0.46) | POLBSCN9AKDM4AMAPK1ATM | |
| SCHEMBL3127618 | 0.82 | KDM4A (0.43) | POLBSCN9AKDM4AMAPK1ATM | |
| SCHEMBL29473242 | 0.82 | KDM4A (0.43) | POLBSCN9AKDM4AMAPK1ATM | |
| SCHEMBL29076001 | 0.82 | POLB (0.44) | POLBLMNACYP3A4SCN9AKDM4A | |
| SCHEMBL20049207 | 0.82 | LMNA (0.48) | POLBLMNACACNA1HCACNA1BCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111333548-B | Preparation method of 1- (2-fluoro-6- (trifluoromethyl) benzyl) urea | 江苏海悦康医药科技有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-111333548-A | Preparation method of 1- (2-fluoro-6- (trifluoromethyl) benzyl) urea | 江苏海悦康医药科技有限公司 | 2020-06-26 | — | — | CN | claimed |
| US-11377426-B2 | Processes to produce elagolix | SUZHOU PENGXU PHARMATECH CO., LTD. (CN) | 2022-07-05 | — | — | US | disclosed |
| CN-111333548-B | Preparation method of 1- (2-fluoro-6- (trifluoromethyl) benzyl) urea | 江苏海悦康医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-111333548-B | Preparation method of 1- (2-fluoro-6- (trifluoromethyl) benzyl) urea | 江苏海悦康医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20210214318-A1 | PROCESSES TO PRODUCE ELAGOLIX | SUZHOU PENGXU PHARMATECH CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| US-20210078956-A1 | PROCESS FOR PREPARING ELAGOLIX SODIUM AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2021-03-18 | — | — | US | disclosed |
| CN-111333548-A | Preparation method of 1- (2-fluoro-6- (trifluoromethyl) benzyl) urea | 江苏海悦康医药科技有限公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-111333548-A | Preparation method of 1- (2-fluoro-6- (trifluoromethyl) benzyl) urea | 江苏海悦康医药科技有限公司 | 2020-06-26 | — | — | CN | disclosed |
| WO-2019112968-A1 | PROCESSES TO PRODUCE ELAGOLIX | WANG PENG (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214318-A1 | PROCESSES TO PRODUCE ELAGOLIX | ELAVL1, ELOB, ELOVL3 | POLB 300/4885LMNA 3009/4885CACNA1H 4852/4885 |
| US-20210078956-A1 | PROCESS FOR PREPARING ELAGOLIX SODIUM AND INTERMEDIATES THEREOF | OGG1, ELP1, UNG | POLB 40/4885LMNA 312/4885CACNA1H 4851/4885 |
| US-11377426-B2 | Processes to produce elagolix | ELAVL1, ELOB, ELOVL3 | POLB 300/4885LMNA 3009/4885CACNA1H 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.